Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116582

The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.

K Tsutsumi, Y Inoue, A Shima, K Iwasaki, M Kawamura, and T Murase

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Tsutsumi, K. in: PubMed | Google Scholar

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Inoue, Y. in: PubMed | Google Scholar

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Shima, A. in: PubMed | Google Scholar

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Iwasaki, K. in: PubMed | Google Scholar

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Kawamura, M. in: PubMed | Google Scholar

New Drug Research Laboratory, Naruto Research Institute, Otsuka Pharmaceutical Factory, Incorporated, Tokushima, Japan.

Find articles by Murase, T. in: PubMed | Google Scholar

Published July 1, 1993 - More info

Published in Volume 92, Issue 1 on July 1, 1993
J Clin Invest. 1993;92(1):411–417. https://doi.org/10.1172/JCI116582.
© 1993 The American Society for Clinical Investigation
Published July 1, 1993 - Version history
View PDF
Abstract

We have discovered a novel compound, NO-1886, which possesses a powerful lipoprotein lipase (LPL) activity-increasing action. Administration of NO-1886 increased LPL activity in the postheparin plasma, adipose tissue, and myocardium of rats, and produced a reduction in plasma triglyceride levels with concomitant elevation of HDL cholesterol levels. Administration of NO-1886 increased LPL enzyme mass in postheparin plasma and mRNA activity in epididymal adipose tissue, and it was concluded that the mode of action of this compound is stimulation of tissue LPL synthesis. We also conducted long-term studies to assess the impact of increases in LPL activity and HDL levels on the development of atherosclerotic lesions in rats. Administration of NO-1886 for as long as 90 d significantly decreased the degree of atherosclerotic changes in the coronary arteries of vitamin D2-treated, cholesterol-fed rats. Statistical analysis indicated that increased concentration of HDL is the factor contributing mostly to the prevention of coronary artery sclerosis. In summary, the results of our study indicate that compound NO-1886 increases LPL activity, causing an elevation in HDL levels, and that long-term administration of NO-1886 to rats with experimental atherosclerosis provides significant protection against the development of coronary artery lesions.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 411
page 411
icon of scanned page 412
page 412
icon of scanned page 413
page 413
icon of scanned page 414
page 414
icon of scanned page 415
page 415
icon of scanned page 416
page 416
icon of scanned page 417
page 417
Version history
  • Version 1 (July 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts